Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 13Breast Neoplasms 11Carcinoma, Transitional Cell 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 3Small Cell Lung Carcinoma 2Urothelial Bladder Carcinoma 1Salivary Gland Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1HRD Cancer 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Small Cell 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Injections 8pembrolizumab 4Pemetrexed 4Carboplatin 4Oxaliplatin 3Leucovorin 3Fluorouracil 3trifluridine tipiracil drug combination 2sotorasib 2fludarabine 2Paclitaxel 2Drug Therapy 2Docetaxel 2Bevacizumab 2zimberelimab 1trametinib 1toripalimab 1tislelizumab 1sacituzumab govitecan 1palbociclib 1netrin-1 inhibitor NP137 1cemiplimab 1WW Domain-Containing Oxidoreductase 1SYS6006 COVID-19 vaccine 1Panitumumab 1Irinotecan 1Immune Checkpoint Inhibitors 1Fulvestrant 1Etoposide 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumors × sacituzumab govitecan × 90 days × Clear all
NCT06167317 2026-05-28

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
278 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡